E.g., 03/28/2024
E.g., 03/28/2024

bioMérieux Launches a Simple and Rapid VIDAS® L. monocytogenes Testing Solution to Improve Food Safety

19 January, 2010

3_vidasslide31_thumb16.jpg VIDAS® LMX, a New VIDAS Next Day test for food and environmental testing.

bioMérieux Acquires Chinese Rapid Test Manufacturer Meikang BioTech

14 January, 2010

Company to leverage new production site to capture growth in China and expand Point of Care and rapid diagnostics offer for both emerging and developed countries

Sepsis and Septic Shock on the Rise, Affecting Younger Patients

11 January, 2010

Physicians Attribute Antimicrobial Resistance and the Spread of Multi-Drug Resistant Organisms (MDRO) to Antibiotic Overuse

Philips and bioMérieux Announce Partnership to Develop and Market Next-Generation Handheld Diagnostic Solutions for Point-of-Care

07 January, 2010

Fully automated handheld diagnostic test devices designed to improve diagnosis and disease management in critical care settings within hospitals.

bioMérieux Launches VIDAS® Free PSA rt BioMarker for Prostate Cancer

05 January, 2010

New test provides physicians with additional information which may eliminate invasive biopsies

bioMérieux Recognized for Outstanding Service in Physician Office Distribution Network

14 December, 2009

bioMérieux, a world leader in the field of in vitro diagnostics, has been named the recipient of the Rising Star Award by National Distribution & Contracting, Inc. (NDC) for its outstanding service and support in the physician office market.

Data from Three Clinical Studies of bioTheranostics' Breast Cancer Molecular Test Presented at CTRC-AACR San Antonio Breast Cancer Symposium

12 December, 2009

Independent studies validate the utility of THEROS BCI® for risk stratification of early stage breast cancer patients and prediction of response to commonly used aromatase inhibitor

Mérieux Alliance Becomes Institut Mérieux

07 December, 2009

Alain Mérieux confirms the Institute’s commitment to meeting new medical and public health challenges

Long-Term Strategic Partnership Between bioMérieux and the CEA to Develop Innovative Technologies for Infectious Disease Management

03 December, 2009

bioMérieux and the CEA (French Atomic Energy Commission) announce today a long-term strategic partnership, intensifying their research collaboration to develop novel technologies for improved infectious disease management.

bioMérieux's TEMPO® Gains Approval for Testing E. Coli in Food Samples

01 December, 2009

pr_tempo_small_thumb19.jpg bioMérieux, a world leader in the field of in vitro diagnostics, is pleased to announce that TEMPO® EC, an automated quality indicator test for the fast enumeration of Escherichia coli in food products, has been granted Official Methods of Analysis (OMA) approval by AOAC INTERNATIONAL. This added level of certification assures TEMPO EC users that the test meets stringent AOAC standards for excellence in indicator testing.

Pioneering Diagnostics